What is Arbutus Biopharma Corporation's G&A?

Arbutus Biopharma Corporation (ABUS) reported G&A of $5.89M in Q1 2026.

How has Arbutus Biopharma Corporation's G&A changed year-over-year?

Arbutus Biopharma Corporation's G&A increased by 1.0% year-over-year, from $5.83M to $5.89M.

What is the long-term trend for Arbutus Biopharma Corporation's G&A?

Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's G&A has grown at a -1.9% compound annual growth rate (CAGR), from $17.14M to $15.89M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Arbutus Biopharma Corporation ABUS G&A

G&A at other companies

AnaptysBio, Inc.ANAB

$26.2M+85.4%

Avalo TherapeuticsAVTX

$6.85M+23.6%

Aurinia PharmaceuticalsAUPH

$22.03M+8.3%

Lantheus HoldingsLNTH

$57.53M+1.3%

Beam TherapeuticsBEAM

$34.43M+23.2%

Ligand PharmaceuticalsLGND

$20.84M+10.8%

Segments

By segment

See full

Reportable Segment$5.89M+1.0%

Other financials

Income statement

See full

Revenue$179.1M+10,055%

Operating income$168.9M+757%

Net income$169.7M+792%

EPS (diluted)$0.87+769%

Balance sheet

See full

Cash & equivalents$23.7M-36.1%

Total debt$631.0K-46.9%

Total equity$260.2M+229%

Total assets$277.2M+137%

Cash flow

See full

Operating cash flow-$8.1M+39.4%

CapEx--100%

Free cash flow-$4.7M+55.0%

Valuation

See full

Market cap$881.02M+32.6%

Enterprise value$857.94M+36.6%

P/E5.5×—

P/S4.6×-99.1×

Profitability

See full

Operating margin81.7%+42.1pp

Net margin84%+43.4pp

FCF margin-281.5%-119pp

Returns & leverage

See full

Return on equity94.7%+65.1pp

Debt / equity0×0.0×

Current ratio54.3×+48.3×

Where this comes from

Reported directly by Arbutus Biopharma Corporation in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arbutus Biopharma Corporation's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Arbutus Biopharma Corporation's G&A?: Arbutus Biopharma Corporation (ABUS) reported G&A of $5.89M in Q1 2026.
How has Arbutus Biopharma Corporation's G&A changed year-over-year?: Arbutus Biopharma Corporation's G&A increased by 1.0% year-over-year, from $5.83M to $5.89M.
What is the long-term trend for Arbutus Biopharma Corporation's G&A?: Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's G&A has grown at a -1.9% compound annual growth rate (CAGR), from $17.14M to $15.89M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.